{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:06Z","timestamp":1792012326803,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ruxolitinib with lenalidomide and dexamethasone shows anti\u2010myeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma (MM) cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity to lenalidomide. A phase I trial was conducted to determine the safety and efficacy of ruxolitinib with lenalidomide and methylprednisolone for patients with relapsed\/refractory (RR)MM who had been treated with lenalidomide, steroids and a proteasome inhibitor and showed progressive disease at study entry. A traditional 3\u00a0+\u00a03 dose escalation design was used to enroll subjects in four cohorts. Subjects received ruxolitinib twice daily, lenalidomide daily on days 1\u201321 of a 28\u00a0day cycle and methylprednisolone orally every other day. Primary endpoints were safety, clinical benefit rate (CBR) and overall response rate (ORR). Forty\u2010nine patients were enrolled. The median age was 64\u00a0years and they had received a median of six prior treatments including lenalidomide and steroids to which 94% were refractory. No dose limiting toxicities occurred. The CBR and ORR were 49% and 36%, respectively. All responding patients were refractory to lenalidomide. Grade 3 or 4 adverse events (AEs) included anemia (17%), decreased lymphocyte count (15%), and hypophosphatemia (10%). Most common serious AEs included sepsis (9.8%) and pneumonia (7.8%). This Phase I trial demonstrates that a JAK inhibitor, ruxolitinib, can overcome refractoriness to lenalidomide and steroids for patients with RRMM. These results represent a promising novel therapeutic approach for treating MM. NCT03110822.<\/jats:p>","DOI":"10.1002\/hon.3066","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:23:11Z","timestamp":1660108991000},"page":"906-913","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed\/refractory multiple myeloma patients"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"first","affiliation":[{"name":"Berenson Cancer Center West Hollywood  Los Angeles California USA"},{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"},{"name":"Institute for Myeloma and Bone Cancer Research West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Kim","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"To","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Spektor","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Martinez","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley","family":"Turner","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ghermezi","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Eades","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina A.","family":"Swift","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center West Hollywood  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[{"name":"Compassionate Care Research Group Fountain Valley  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Moss","sequence":"additional","affiliation":[{"name":"F.A.C.P., Inc, Fountain Valley  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lim","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.1.11"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"4","article-title":"Advances in the biology and treatment of myeloma","volume":"105","author":"Morgan GJ","year":"1999","journal-title":"Br J Haematol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008331714186"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102000\u20106860"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.003"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s1445"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.91192"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210757"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010019\u201003595\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050\u20107771\u20101\u20105"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.259"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21785"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.175"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24911"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0960\u20100760(02)00223\u20106"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.913024"},{"key":"e_1_2_11_18_1","article-title":"The role of JAK2 inhibition in polycythemia vera","author":"Mascarenhas J","year":"2018","journal-title":"Targeted Oncol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.4106.4106"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14801"},{"key":"e_1_2_11_21_1","article-title":"Jak1\/2 pathway inhibition suppreses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","author":"Chen H","year":"2019","journal-title":"Br J Haematol"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100242\u20106"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010119099"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201002\u2010700872"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2259"},{"key":"e_1_2_11_29_1","article-title":"JAK inhibitors used as anti\u2010inflammatory therapeutics for pancreatic cancer","author":"Garrido\u2010Laguna I","year":"2015","journal-title":"Contemp Oncol"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.06.016"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.2114.2114"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.3066","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T10:10:52Z","timestamp":1692439852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,14]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/hon.3066"],"URL":"https:\/\/doi.org\/10.1002\/hon.3066","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3066\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3066\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3066\/v1\/review1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,14]]},"assertion":[{"value":"2022-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}